Loading
A phase 2 trial of atezolizumab and sacituzumab govitecan in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting.
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA). ClinicalTrials.gov record last updated 2026-05-04: recruiting. Enrollment is planned at 40 participants. Primary completion is estimated at 2026-12-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Atezolizumab, Sacituzumab govitecan. Registered primary measures: Rate of undetectable circulating tumor cfDNA- 6 Cycles.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares TROP2, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/